BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: García-Bosch O, Aceituno M, Ordás I, Etchevers J, Sans M, Feu F, Panés J, Ricart E. Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response-An Observational Study. Dig Dis Sci 2016;61:2051-9. [PMID: 26921082 DOI: 10.1007/s10620-016-4089-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 van Gennep S, Sahami S, Buskens CJ, van den Brink GR, Ponsioen CY, D'Hoore A, de Buck van Overstraeten A, van Assche G, Ferrante M, Vermeire S, Bemelman WA, D'Haens GR, Löwenberg M. Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy. Eur J Gastroenterol Hepatol 2017;29:338-44. [PMID: 27902515 DOI: 10.1097/MEG.0000000000000798] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
2 Gonczi L, Vegh Z, Golovics PA, Rutka M, Gecse KB, Bor R, Farkas K, Szamosi T, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Papp M, Patai Á, Salamon Á, Tóth GT, Vincze Á, Biro E, Lovasz BD, Kurti Z, Szepes Z, Molnár T, Lakatos PL. Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role? J Crohns Colitis 2017;11:697-705. [PMID: 27838610 DOI: 10.1093/ecco-jcc/jjw203] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
3 Macaluso FS, Cavallaro F, Felice C, Mazza M, Armuzzi A, Gionchetti P, Vecchi M, Orlando A. Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. Dig Liver Dis 2019;51:613-20. [PMID: 30826279 DOI: 10.1016/j.dld.2019.01.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Seo H, Chang K, Lee S, Song E, Kim G, Seo M, Lee H, Hwang S, Yang D, Kim K, Ye BD, Byeon J, Myung S, Yang S, Park SH. Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea. Scandinavian Journal of Gastroenterology 2017;52:857-63. [DOI: 10.1080/00365521.2017.1323229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
5 Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis 2020;14:351-60. [DOI: 10.1093/ecco-jcc/jjz152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
6 Srinivasan A, van Langenberg DR. Editorial: does anti-TNF "treatment persistence" always equate to "effective treatment"? Only objective disease assessments can answer the question. Aliment Pharmacol Ther 2021;54:718-9. [PMID: 34379842 DOI: 10.1111/apt.16506] [Reference Citation Analysis]
7 Sayar S, Kurbuz K, Kahraman R, Caliskan Z, Atalay R, Ozturk O, Doganay HL, Ozdil K. A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. North Clin Istanb. 2020;7:49-55. [PMID: 32232203 DOI: 10.14744/nci.2018.78800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Fradet C, Kern J, Atanasov P, Wirth D, Borsi A. Impact of surgery and its complications in ulcerative colitis patients in clinical practice: A systematic literature review of real-world evidence in Europe. International Journal of Surgery Open 2020;22:22-32. [DOI: 10.1016/j.ijso.2019.11.010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Taxonera C, Iglesias E, Muñoz F, Calvo M, Barreiro-de Acosta M, Busquets D, Calvet X, Rodríguez A, Pajares R, Gisbert JP, López-Serrano P, Pérez-Calle JL, Ponferrada Á, De la Coba C, Bermejo F, Chaparro M, Olivares D, Alba C, Fernández-Blanco I. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. Dig Dis Sci 2017;62:481-90. [PMID: 27995400 DOI: 10.1007/s10620-016-4398-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
10 Blesl A, Binder L, Högenauer C, Wenzl H, Borenich A, Pregartner G, Berghold A, Mestel S, Kump P, Baumann-Durchschein F, Petritsch W. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther 2021;54:667-77. [PMID: 34151449 DOI: 10.1111/apt.16478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]